Verona Pharma initiated with a Buy at Roth MKM
Roth MKM analyst Boobalan Pachaiyappan initiated coverage of Verona Pharma (VRNA) with a Buy rating and $68 price target The firm says its ...
Verona Pharma’s Ohtuvayre: Unique COPD Solution Drives Buy Rating Amid Market Potential and Revenue Growth
Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA).Stay Ahead of the Market:Discover ...
Verona Pharma (NASDAQ:VRNA) Price Target Raised to $74.00
Verona Pharma (NASDAQ:VRNA – Get Free Report) had its price target raised by investment analysts at Wells Fargo & Company ...
Hosted on MSN6h
Verona Pharma (VRNA) Upgraded to Buy: What Does It Mean for the Stock?
Verona Pharma PLC American Depositary Share (VRNA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...
Contract Pharma8h
Verdiva Bio Launches as Clinical-Stage Cardiometabolic Company
With over $410 million in financing; to advance portfolio of next-gen oral and injectable treatments with first- or ...
beautypackaging11h
Virospack Owner Strikes Deal with Eurovetrocap
Eurovetrocap’s founding family will retain a minority stake in the company, and the existing management team will remain in ...
Indiatimes5h
Nifty Pharma
What does Nifty Pharma represent? Tracks the performance of pharmaceutical companies in India, comprising leading pharmaceutical stocks listed on the National Stock Exchange (NSE), reflecting trends ...